#None #Epilepsy #Dementia Risk #hearing decline

Hearing Aids and Dementia Risk Reduction in Epilepsy Patients

Recent findings presented at the European Academy of Neurology (EAN) Congress reveal significant insights into the relationship between hearing aids and dementia risk among adults suffering from both epilepsy and hearing loss. The study indicates that individuals who utilize hearing aids may have a 23% lower risk of developing dementia compared to their counterparts who do not use these devices.

Hearing loss has long been established as a major modifiable risk factor for dementia. However, the extent to which hearing aid use can mitigate this risk has been a subject of contention and varied conclusions. In an extensive study conducted by researchers from the University Hospital Zurich and the University of Liverpool, over 250 million patient records from the TriNetX network were analyzed to discern these connections.

This comprehensive analysis compared adults experiencing hearing loss who employed hearing aids with a control group exhibiting similar characteristics but who were not using hearing aids. The research accounted for various underlying conditions, including epilepsy, stroke, Type 2 diabetes, chronic kidney disease, heart failure, migraines, and osteoarthritis.

While overall data among the hearing-impaired population showed no significant correlation between hearing aid usage and decreased dementia risk—regardless of the presence of other health conditions—adults with both epilepsy and hearing loss exhibited a noteworthy trend. The use of hearing aids was associated with a 23% reduction in their dementia risk. This translated to an absolute risk reduction of 2.7 percentage points over a five-year span, suggesting one less case of dementia per 37 hearing aid users within this specific demographic.

The principal investigator, Dr. Carolina Ferreira-Atuesta, explained that the results could be interpreted through the lens of cognitive reserve, which refers to the brain’s ability to remain functional despite age-related changes or damage stemming from diseases. She elaborated, “Most individuals with hearing loss possess sufficient cognitive reserve to offset the additional effort demanded by their hearing impairment, implying that rectifying the loss may not yield a substantial effect on the dementia risk.”

In contrast, epilepsy impacts cognitive reserve as it is often already compromised, which may mean that alleviating additional stressors, such as hearing loss, could have a more pronounced impact.

Dr. Ferreira-Atuesta also highlighted several biologically plausible mechanisms that could explain why this protective effect is observed in epilepsy patients. She pointed out that epilepsy is associated with accelerated cognitive decline. Furthermore, temporal lobe epilepsy affects regions of the brain responsible for hearing, and certain anti-seizure medications may contribute to hearing impairment.

These findings carry significant implications for clinical practices. Given that individuals with epilepsy frequently interact with healthcare systems, the integration of hearing tests into routine medical assessments could pave the way for improved outcomes and aid in dementia risk management.

In conclusion, the linkage between hearing aid utilization and reduced dementia risk among adults with epilepsy and hearing loss underscores the importance of addressing hearing impairment within this vulnerable population. Empowering these individuals with tools to enhance their auditory capabilities may not only improve their quality of life but also contribute positively to their cognitive health in the long run.